Pharmacokinetics and Imaging of (212)Pb-TCMC-Trastuzumab After Intraperitoneal Administration in Ovarian Cancer Patients

Purpose: Study distribution, pharmacokinetics, and safety of intraperitoneal (IP) (212)Pb-TCMC-trastuzumab in patients with HER-2-expressing malignancy. Experimental Design: IP (212)Pb-TCMC-trastuzumab was delivered, after 4 mg/kg intravenous (IV) trastuzumab, to 3 patients with HER-2-expressing can...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Meredith, Ruby F., Torgue, Julien, Azure, Michael T., Shen, Sui, Saddekni, Souheil, Banaga, Eileen, Carlise, Ronda, Bunch, Patty, Yoder, Daniel, Alvarez, Ronald
Format: Artigo
Idioma:Inglês
Publicat: Mary Ann Liebert, Inc. 2014
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3869429/
https://ncbi.nlm.nih.gov/pubmed/24229395
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/cbr.2013.1531
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars